AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Highlights
- Cynata Therapeutics Limited (ASX:CYP) has received Notice of Allowance from the US Patent Office for the use of Cymerus™ technology to treat Asthma and allergic airways disease.
- The US patent will strengthen the Company’s IP portfolio protecting its proprietary manufacturing platform.
- Cymerus™ has a major competitive advantage of producing MSCs economically at commercial scale from a single donor, for therapeutic use.
In its latest announcement, Cynata Therapeutics Limited (ASX:CYP) revealed that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the use of the Company’s proprietary Cymerus™ manufacturing platform in Asthma and allergic airways disease (AAD).
Asthma is a chronic lung condition that affects more than 330 million people worldwide and causes nearly 1,000 deaths daily. Cynata believes that Cymerus technology can be a game changer in the treatment of the long-term lung condition. Various studies have demonstrated that Cymerus™ mesenchymal stem cells (MSCs) have a strongly positive impact on all significant components of Asthma, namely airway hyperresponsiveness, airway remodeling and airway inflammation. It has been observed that Cymerus™ MSCs significantly reduce inflammation as well as fibrosis in a model of asthma.
Image Source: © Ohotniknautok | Megapixl.com
Focal points of the US patent application
The patent application entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma” is completely owned by Cynata. It is regarding the use of Cymerus™ mesenchymal stem cell (MSC) technology to target asthma and allergic airways disease (AAD).
The inventors are:
- Dr Simon Royce, Research Fellow, Department of Pharmacology at Monash University
- Professor Chrishan Samuel, a Monash Biomedicine Discovery Fellow and Head of the Fibrosis Laboratory
As per the standard procedure, the US Patent Office issues Notice of Allowance to the applicant only if it holds the intention to issue a patent. If issued, the US patent will be valid till 2038.
Significance of US Patent
Cymerus™ has a major competitive advantage as it can produce MSCs economically at a commercial scale, without needing multiple donors, to create therapeutic stem cell products. This serves as the key to the fast-paced development of therapeutic stem cell products for the treatment of multiple devastating diseases at a global level. The US patent will further affirm this unique ability of the manufacturing platform.
With a US patent for Cymerus™ MSCs in AAD, the biotechnology company will hit another major milestone. It will add significant value to the Company’s portfolio of wholly owned patents and patent applications. The patent will strengthen its comprehensive IP (intellectual property) protection of the Cymerus™ technology.
Management Commentary
Cynata shares were spotted at A$0.380, as of 10:51 AM AEST on 14 July 2022.
To understand the role of iPSCs in the manufacture of Cynata's Cymerus™ MSCs, click here.
